<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30144661</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>21</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1879-0852</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>102</Volume>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                    </PubDate>                </JournalIssue>                <Title>European journal of cancer (Oxford, England : 1990)</Title>                <ISOAbbreviation>Eur. J. Cancer</ISOAbbreviation>            </Journal>            <ArticleTitle>Ten-year conditional recurrence risks and overall and relative survival for breast cancer patients in the Netherlands: Taking account of event-free years.</ArticleTitle>            <Pagination>                <MedlinePgn>82-94</MedlinePgn>            </Pagination>            <ELocationID EIdType="pii" ValidYN="Y">S0959-8049(18)31093-1</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejca.2018.07.124</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Survival estimates from diagnosis are of limited importance for (ex-)breast cancer patients who survived several years, as it includes information on already deceased patients. This study analysed the 10-year conditional risk of recurrent breast cancer in specific prognostic subgroups. Second, we investigated 10-year conditional overall survival (OS) and relative survival (RS), adjusted for confounding.</AbstractText>                <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">All women diagnosed in 2005 with operated T1-2N0-1 breast cancer were selected from the Netherlands Cancer Registry. Patients were classified into T1N0, T1N1, T2N0 and T2N1 stage. Ten-year conditional recurrence rates were calculated from diagnosis, and for patients without an event (local [LR], regional recurrence [RR], distant metastasis [DM] or death) every year following diagnosis. Ten-year conditional OS was calculated using multivariable Cox regression. RS was estimated by dividing patient survival rates by those of the general Dutch population.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">We included 7969 patients: 52.3% had T1N0, 15.3% T1N1, 19.9% T2N0 and 12.5% T2N1 stage. For T1N0, 10-year LR rates changed from 4.6% at diagnosis to 0.5% in year 10. RR rates changed from 2.3% to 0.2%, and DM rates changed from 7.8% to 0.6%. For T2N1 stage, the LR, RR and DM rates changed from 6.2% to 0.8%, 5.2%-0.4% and 19.6%-1.5%, respectively. For the luminal A subtype, LR, RR and DM rates changed from 3.9% to 0.4%, 1.7%-0.5% and 7.3%-1.1%, while for triple negative, these rates changed from 5.6% to 0.7%, 4.9%-0.2% and 16.7%-0%, respectively. Differences between subgroups attenuated over time, and all recurrence rates became ≤1.5% in year 10. Ten-year OS and RS, adjusted for confounding, showed declining risk differences between subgroups over time.</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Differences in recurrence rates, OS and RS between prognostic subgroups declined as years passed by. These results highlight the importance of taking into account disease-free years to more accurately predict (ex-)breast cancer patients' prognosis over time.</AbstractText>                <CopyrightInformation>Copyright © 2018 Elsevier Ltd. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>van Maaren</LastName>                    <ForeName>Marissa C</ForeName>                    <Initials>MC</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Research, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands; Department of Health Technology &amp; Services Research, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands. Electronic address: m.vanmaaren@iknl.nl.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Strobbe</LastName>                    <ForeName>Luc J A</ForeName>                    <Initials>LJA</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgical Oncology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Smidt</LastName>                    <ForeName>Marjolein L</ForeName>                    <Initials>ML</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgical Oncology, Maastricht University Medical Centre, Maastricht, The Netherlands.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Moossdorff</LastName>                    <ForeName>Martine</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgical Oncology, Zuyderland Medical Centre, Sittard-Geleen, The Netherlands.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Poortmans</LastName>                    <ForeName>Philip M P</ForeName>                    <Initials>PMP</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Radiation Oncology, Institut Curie, Paris, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Siesling</LastName>                    <ForeName>Sabine</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Research, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands; Department of Health Technology &amp; Services Research, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>23</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Eur J Cancer</MedlineTA>            <NlmUniqueID>9005373</NlmUniqueID>            <ISSNLinking>0959-8049</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">10-Year survival</Keyword>            <Keyword MajorTopicYN="N">Breast cancer</Keyword>            <Keyword MajorTopicYN="N">Conditional survival</Keyword>            <Keyword MajorTopicYN="N">Recurrence</Keyword>            <Keyword MajorTopicYN="N">Relative survival</Keyword>            <Keyword MajorTopicYN="N">Survivors</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>05</Month>                <Day>17</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>07</Month>                <Day>13</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>16</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>26</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>26</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>26</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30144661</ArticleId>            <ArticleId IdType="pii">S0959-8049(18)31093-1</ArticleId>            <ArticleId IdType="doi">10.1016/j.ejca.2018.07.124</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>